XOLAIR Allergic Asthma
FDA Reviewing Preliminary XOLAIR Safety Information
XOLAIR Safety Information
Free XOLAIR Lawsuit Review
Problems with XOLAIR Have Been Linked to Heart Attack and Stroke
You or a loved one may be entitled to financial compensation if injury or death occurred while taking these medicines.
The FDA is evaluating interim safety findings from an ongoing study of XOLAIR (omalizumab) that suggests an increased number of cardiovascular and cerebrovascular adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group). XOLAIR (omalizumab) is an injected drug for asthma related allergies. The FDA originally approved XOLAIR in 2003 but announced in February of 2007 that it was requesting a stronger warning because XOLAIR may cause anaphylaxis, a reaction that may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat.
The FDA went on to reference in their April 17, 2007 notice to consumers that:
- Patients may develop anaphylaxis after any dose of Xolair, even if there was no reaction to the first dose.
- Anaphylaxis after administration of Xolair may be delayed up to 24 hours after the dose is given.
- Health care providers should be prepared to manage life-threatening anaphylaxis following Xolair administration and observe patients for at least two hours after an injection.
- Following administration of Xolair, patients should carry and know how to initiate emergency self-treatment for anaphylaxis.
On July 17, 2009 the FDA announced that it was reviewing preliminary safety information on XOLAIR, stating that:
Reviewers are looking for a possible association between patients who use Xolair and an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke.
The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The study is being conducted by the manufacturer, San Francisco-based Genentech Inc. Results from the drug manufacturer's EXCELS study are not expected until 2012.
Although the FDA and the drug manufacturer have not recalled XOLAIR, the FDA wants consumers to be aware of increased risks from taking XOLAIR, specifically heart attack/heart disease and stroke.
If you believe that you or a loved one has suffered hospitalization or death as a result of using XOLAIR, fill out our online form or call us toll free at 1-877-DRUG-101.
Onder, Shelton, O'Leary & Peterson, LLC is a law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O'Leary & Peterson has represented clients throughout the United States, and other firms throughout the nation often seek its experience and expertise on complex litigation. For more information, visit www.onderlaw.com or call 1-877-DRUG-101.
Onder, Shelton, O’Leary & Peterson, LLC
XOLAIR Safety Information
The choice of a lawyer is an important decision and should not be based solely upon advertisements.
Disclaimer: The accident, injury, personal injury, and/or other legal information offered herein by The Onder Law firm, is not formal legal advice, nor is it the formation of an attorney client relationship. In order for our firm to be considered your attorney there must be a signed agreement between the client and the firm. Any results set forth herein are based solely upon the circumstances of that particular case and offer no promise or guarantee on the outcome of any other case.